Drug Recall Enforcement Report Class I voluntary initiated by B. Braun Medical Inc, originally initiated on 10-15-2013 for the product Cefepime for Injection USP and Dextrose Injection USP, in Duplex Drug Delivery System, 1 g in 50 mL duplex container, For IV Use Only, Single Dose, Sterile/Non pyrogenic, Rx Only, B Braun Medical Inc., NDC 0264-3193-11 The product was recalled due to presence of particulate matter: the 1g cefepime for injection usp and dextrose injection usp lot has been found to contain visible organic particulate matter in a reserve sample unit.. The product was distributed nationwide and the recall is currently terminated.
Field Name |
Field Value |
Event ID |
66497 What is the Event ID? A numerical designation assigned by FDA to a specific recall event (used for tracking purposes). |
Recall Number |
D-1054-2014 What is the Recall Number? An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes). |
Recall Classification |
Class I - is a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death. What is the Recall Classification? Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified". |
Distribution Pattern |
Nationwide What is the Distribution Pattern? General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included. |
Product Description |
Cefepime for Injection USP and Dextrose Injection USP, in Duplex Drug Delivery System, 1 g in 50 mL duplex container, For IV Use Only, Single Dose, Sterile/Non pyrogenic, Rx Only, B Braun Medical Inc., NDC 0264-3193-11 |
Reason For Recall |
Presence of Particulate Matter: The 1g Cefepime for Injection USP and Dextrose Injection USP lot has been found to contain visible organic particulate matter in a reserve sample unit. What is the Reason for Recall? Information describing how the product is defective. |
Product Quantity |
18,936 Containers Product Quantity The amount of product subject to recall. |
Voluntary Mandated |
Voluntary: Firm initiated Voluntary / Mandated Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order. |
Report Date |
02-12-2014 |
Recall Initiation Date |
10-15-2013 What is the Recall Initiation Date? The date that the firm first began notifying the public or their consignees of the recall. |
Termination Date |
12-04-2014 What is the Date Terminated? The date that FDA terminated the recall. |
Initial Firm Notification |
Press Release Initial Firm Notification of Consignee or Public The method(s) by which the firm initially notified the public or their consignees of a recall. |
Product Type |
Drugs |
Recalling Firm |
B. Braun Medical Inc |
Code Info |
Lot H3A744, Exp 01/15 Code Information A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling. |
Recalled NDC Packages |
0264-3193-11; 0264-3195-11 |
Status |
Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard. |
Recalled Products
NDC |
Proprietary Name |
Non-Proprietary Name |
Dosage Form |
Route Name |
Company Name |
Product Type |
0264-3193 | Cefepime Hydrochloride And Dextrose | Cefepime Hydrochloride | Injection, Solution | Intravenous | B. Braun Medical Inc. | Human Prescription Drug |
0264-3195 | Cefepime Hydrochloride And Dextrose | Cefepime Hydrochloride | Injection, Solution | Intravenous | B. Braun Medical Inc. | Human Prescription Drug |